ACM
HRMY icon

Aster Capital Management’s Harmony Biosciences HRMY Stock Holding History

Aster Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-105
Closed -$3.48K – 1030
2026
Q1 		$3.48K Buy
+105
New +$3.44K ﹤0.01% 712
2025
Q3 		– Sell
-152
Closed -$4.8K – 1143
2025
Q2 		$4.8K Buy
+152
New +$4.89K ﹤0.01% 871
2025
Q1 		– Sell
-557
Closed -$19.2K – 1439
2024
Q4 		$19.2K Buy
+557
New +$19.1K 0.01% 642

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's HRMY Position: Q2 2026 in Review

Aster Capital Management sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 105 shares — an estimated $3.48K sold.

Aster Capital Management first reported a position in HRMY in Q4 2024 and held it in 3 quarters. The position peaked at $19.2K in Q4 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Aster Capital Management reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 105 Harmony Biosciences shares in Q2 2026, an estimated $3.48K.
  • Aster Capital Management first reported a position in Harmony Biosciences in Q4 2024 and held it in 3 quarters.
  • Aster Capital Management's Harmony Biosciences position peaked at $19.2K in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.